Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.

被引：0

作者：

Celio, Luigi

Bonizzoni, Erminio

Bria, Emilio

机构：

[1] Desenzano Garda Hosp, Oncol Unit, ASST Garda, Brescia, Italy

[2] Univ Milan, Fac Med & Surg, Sect Med Stat Biometry & Epidemiol GA Maccacaro, Dept Clin Sci & Commun, Milan, Italy

[3] Univ Cattolica Sacro Cuore, IRCCS, Fdn Policlin Univ Agostino Gemelli, Med Oncol,Comprehens Canc Ctr, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.12093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

12093

引用

页数：3

共 50 条

[31] Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)
Jahn, P.
Jordan, K.
Rizzi, G.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S20 - S21
[32] Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.
Aapro, Matti S.
Karthaus, Meinolf
Schwartzberg, Lee Steven
Rossi, Giorgia
Rizzi, Giada
Borroni, Maria Elisa
Palmas, Marco
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[33] Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT)
Grote, T
Hajdenberg, J
Cartmell, A
Ferguson, S
Ginkel, A
Gallagher, S
Charu, V
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 794S - 794S
[34] FIXED COMBINATION NETUPITANT AND PALONOSETRON IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN THE UK
D'agostino, P.
Cawston, H.
Bourhis, F.
Turini, M.
Ruffo, P.
Mcguire, A.
VALUE IN HEALTH, 2015, 18 (07) : A461 - A461
[35] Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study
Schilling, Joerg
Busch, Steffi
Stefek, Andrea
Muller, Eberhard
Schwickerath, Juergen
Altmann, Falk
Hollander, Martin
Karthaus, Meinolf
CANCER RESEARCH, 2020, 80 (04)
[36] Improved control of nausea and vomiting (CINV) with a fixed-dose combination of netupitant and palonosetron (NEPA) following highly emetogenic chemotherapy (HEC): Results from a pivotal study
Gralla, R.
Rossi, G.
Rizzi, G.
Palmas, M.
Alyasova, A.
Drobner, I.
Hesketh, P.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S267 - S267
[37] The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
Vaswani, Bharat
Dattatreya, Palanki S.
Barkate, Hanmant
Bhagat, Sagar B.
Patil, Saiprasad
Jadhav, Amit Y.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
[38] Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Gilmore, James
Bernareggi, Alberto
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 472 - 487
[39] Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
Hesketh, P. J.
Rossi, G.
Rizzi, G.
Palmas, M.
Alyasova, A.
Bondarenko, I.
Lisyanskaya, A.
Gralla, R. J.
ANNALS OF ONCOLOGY, 2014, 25 (07) : 1340 - 1346
[40] Impact on patients' daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
Aapro, Matti S.
Rossi, Giorgia
Rizzi, Giada
Borroni, Maria Elisa
Nagl, Norman G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)

← 1 2 3 4 5 →